Results 61 to 70 of about 20,527 (318)

Dupilumab in the treatment of severe non-control broncial asthma — economic aspects

Качественная клиническая практика, 2019
Severe non-control Bronchial Asthma (BA) is a sufficient social problem with decreasing of quality of life, high index of disability and death. New biological drug — dupilumab — would improve the situation.Materials and methods.
A. S. Salasyuk, M. Yu. Frolov, I. N. Barykina   +2 more
doaj   +1 more source

The use of dupilumab in severe atopic dermatitis during pregnancy: a case report

Allergy, Asthma & Clinical Immunology, 2022
Background Atopic dermatitis is a common chronic skin disease that can occur in pregnancy. Current treatments include topical and systemic glucocorticoids and cyclosporine.
Nabeel H. Akhtar, Touraj Khosravi-Hafshejani, Daud Akhtar, Gurbir Dhadwal, Amin Kanani   +4 more
doaj   +1 more source

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis

Acta Dermato-Venereologica, 2021
Optimal management of atopic dermatitis requires a comprehensive assessment of response to treatment in order to inform therapeutic decisions. In a real-world setting, successful response to atopic dermatitis treatment is measured by sustained ...
Jonathan I. Silverberg, Eric L. Simpson, Mark Boguniewicz, Marjolein S. De Bruin-Weller, Peter Foley, Yoko Kataoka, Gaëlle Bégo-Le-Bagousse, Zhen Chen, Brad Shumel, Jingdong Chao, Ana B. Rossi   +10 more
doaj   +1 more source

Dupilumab for bullous pemphigoid with intractable pruritus [PDF]

, 2019
Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. Treatment regimens typically include topical and systemic immunosuppressive medications.
Eichenfield, Dawn Z, Orme, Charisse M, Seidman, Jason S   +2 more
core  

Personalized medicine with biologics for severe type 2 asthma : current status and future prospects [PDF]

, 2017
Asthma affects more than 300 million people worldwide and poses a large socioeconomic burden, particularly in the 5% to 10% of severe asthmatics. So far, each entry of new biologics in clinical trials has led to high expectations for treating all severe ...
Blanchetot, Christophe, Brusselle, Guy, de Haard, Hans, Godar, Marie, Lambrecht, Bart   +4 more
core   +3 more sources

Ophiasis treated with dupilumab [PDF]

JAAD Case Reports, 2021
DO Joseph Aleshaki, David Fivenson, DO McKenna Abercrombie   +2 more
openaire   +3 more sources

Dupilumab: a novel treatment for asthma

Journal of Asthma and Allergy, 2014
Simultaneously with the steady progress towards a better knowledge of the pathobiology of asthma, the potential usefulness of anticytokine therapies is emerging as one of the key concepts in the newly developing treatments of this widespread airway disease.
Vatrella, Alessandro, Fabozzi, Immacolata, CALABRESE, Cecilia, Maselli, Rosario, Pelaia, Girolamo   +4 more
openaire   +7 more sources

Association of Tralokinumab and Adalimumab: Good Tolerance and Efficacy in a Case of Severe Atopic Dermatitis and Juvenile Idiopathic Arthritis

JEADV Clinical Practice, EarlyView.
ABSTRACT Atopic dermatitis is a chronic inflammatory and pruritic skin disease. The combination of tralokinumab with adalimumab in the treatment of inflammatory diseases had not yet been documented. It appears promising for treating severe atopic dermatitis in patients with juvenile idiopathic arthritis, offering significant improvement in skin ...
F. Rakotonandrasana, E. Puzenat, A. Ducournau, D. Popescu   +3 more
wiley   +1 more source

Switching to Dupilumab from Other Biologics without a Treatment Interval in Patients with Severe Asthma: A Multi-Center Retrospective Study [PDF]

, 2023
Background: Dupilumab is a fully humanized monoclonal antibody that blocks interleukin4 and interleukin-13 signals. Several large clinical trials have demonstrated the efficacy of dupilumab in patients with severe asthma.
Arakawa, Yukako, Higo, Hisao, Ichikawa, Hirohisa, Itano, Junko, Kataoka, Mikio, Katsuta, Tomoya, Kimura, Goro, Kiura, Katsuyuki, Maeda, Yoshinobu, Miyahara, Nobuaki, Miyake, Kohei, Mori, Yoshihiro, Okayama Respiratory Disease Study Group (ORDSG),, Senoo, Satoru, Taniguchi, Akihiko, Tanimoto, Yasushi   +15 more
core   +1 more source

The Complex Role of IL‐13 in Bullous Pemphigoid: New Insights From a Retrospective Cohort Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease, primarily affecting the elderly. The role of interleukin‐13 (IL‐13) in BP pathogenesis remains unclear, particularly regarding its potential as a therapeutic target.
Marwan Dawood, Zenab Ali Saleh, Ilanit Boyango, Orna Mirmovich Morvay, Salih Mishlab, Ziad Khamaysi, Emily Avitan‐Hersh   +6 more
wiley   +1 more source